Cognivue vs Linus Health (2026)
Both screen cognition with software, with different hardware and different signals. Cognivue runs on dedicated devices: Clarity, a ten minute test for physicians, and Thrive, a five minute screen for pharmacies and hearing care, adapt each exercise to the patient's visual and motor responses through a single control wheel. CARM, an optional machine learning estimate of amyloid likelihood, was added to Clarity in 2025. Linus Health runs on tablets and phones and scores behavior with machine learning. Its Digital Clock and Recall reads how a patient draws a clock and recalls words in about three minutes, and a remote battery lets patients test at home. Cognivue's De Novo from 2015 covered its original device; the devices it sells now, like Linus's platform, are listed under an exempt code. Choose Cognivue for a self contained device in non physician settings; choose Linus for fast screening on common hardware.
- Self administered tests on a dedicated device: a ten minute Clarity test and a five minute Thrive screen.
- Adaptive psychophysics that adjusts each exercise to the patient's visual and motor responses.
- An optional machine learning amyloid risk estimate, CARM, added in 2025.
- A three minute clock drawing and recall test scored by machine learning on behavior.
- A suite of speech, hearing, gait and trail making tools, and a remote battery for home use.
- A report with the recordings behind the score and care pathway guidance.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Cognivue and Linus Health are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Cognivue | Linus Health |
|---|---|---|
| Primary category | Clinical Decision Support | Clinical Decision Support |
| Founded | Not recorded | 2019 |
| Headquarters | Victor, New York, United States | Boston, Massachusetts, United States |
| Website | cognivue.com | linushealth.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Self-administered computerized cognitive assessment on dedicated devices. Cognivue Clarity, a ten minute test for physicians, and Cognivue Thrive, a five minute screen for pharmacies, hearing care practices and other non-physician settings, run on adaptive psychophysics: each exercise adjusts to the patient's visual and motor responses across subtests of memory, executive function and attention, discrimination and visuospatial ability, entered through a single control wheel, and the device prints a report scored against age norms.
Source: AI Health Index, September 2026
Digital cognitive assessment platform that scores drawing, speech and stylus behavior with machine learning models. The flagship Core Cognitive Evaluation combines the Digital Clock and Recall (DCR), a clock drawing and three word recall test of about three minutes built on the DCTclock, with a Life and Health Questionnaire, and returns a provider report with the recordings behind the score, a personalized action plan and care pathway guidance.
Source: AI Health Index, September 2026
Questions buyers ask
How do Cognivue and Linus Health work with the EHR?
For Cognivue, the earlier security features document (RES-001-A, 2023) says an administrator can configure the device to create an HL7 message holding the report, or set up a password protected network file share to reach the report folder. The current Gen5 document (RES-002-A, 2025) mentions only printing, by USB or network.
With Linus Health, the athenahealth Marketplace release (June 2023) says the platform is integrated with athenaOne so results appear in the EHR, with Healthtopia Clinics quoted on results arriving in its record, and a neurology chair at an unnamed California health system describes integration with Cerner on the health systems page. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
How do Cognivue and Linus Health handle patient data?
In Cognivue's case, the Gen5 security features document (RES-002-A, 2025) lists the fields Clarity and Thrive store per test: name, date of birth, sex, subtest and domain scores and, optionally, email and phone number. It says they are kept in a local database on the device, reachable only by on-device processes, under full disk AES-256 encryption, with administrators alone able to open older reports.
Against that, the terms and conditions of sale grant the company a perpetual, irrevocable license to use customer data in aggregated, de-identified form "for the sole purpose of enhancing and improving the Linus Health Services", and the terms of use allow personal data to be used to test, benchmark, enhance and improve products. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Which settings and specialties do Cognivue and Linus Health cover?
With Cognivue, the pharmacy and hearing care settings, where the result is read by a non-physician, carry implementation posters rather than published performance.
In Linus Health's case, the company sells to medical practices and health systems for early detection of cognitive impairment in primary care and specialty triage, to health plans for risk identification and diagnosis capture, and to trial sponsors for prescreening and outcome measurement. The Digital Clock and Recall is sold to detect cognitive impairment and, in the company's research, to estimate amyloid positivity. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
What evidence is published for Cognivue and Linus Health?
The authors are the company's Chief Scientific Officer, university colleagues and Cognivue staff. A competitor's analysis of the same Bio-Hermes cohort (Jannati et al., Alzheimer's Research and Therapy, 2025) reported Cognivue at AUC 0.70 for amyloid status, and the company's chief executive published a Matters Arising on that comparison's method (2026).
With Linus Health, the 2024 Bio-Hermes paper (706 participants) reports AUC 0.70 for the DCR against 0.63 for the MMSE. Both papers are led by company staff with the co-founders among the authors, and the underlying study data are governed by the Global Alzheimer's Platform. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 29, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both records were reviewed on this site in September 2026. Neither company publishes a price. Cognivue's De Novo covered its original device in 2015; its current devices and Linus's platform are listed under the exempt code for computerized cognitive assessment aids.
Ask both how their result is validated against a full neuropsychological assessment, and in whom.